Active Stocks News Analysis: JetBlue Airways Corporation, (NASDAQ:JBLU), Valeant Pharmaceuticals, (NYSE:VRX), Procter & Gamble, (NYSE:PG)

On Tuesday, Shares of JetBlue Airways Corporation (NASDAQ:JBLU), lost -0.45% to $24.57.

JetBlue Airways Corporation, declared that it will redeem all of its outstanding 5.50% convertible debentures due 2038 (Series B) (the Notes) at a redemption price equal to 100% of the principal amount of the Notes, together with accrued and unpaid interest to, but not taking into account, the redemption date. About $22,451,000 of the 5.50% Notes remain outstanding as of October 19, 2015. On and after the date of redemption, interest on the 5.50% Notes will cease to accrue.

We have prepared a notice of redemption and have requested the trustee and paying agent, Wilmington Trust Company, to send the notice of redemption to the registered holders of the Notes on or about October 20, 2015, with an predictable redemption date on November 24, 2015. Notes are to be surrendered to the trustee in exchange for payment of the redemption price. Each holder of the Notes has a right to convert its Notes called for redemption.

JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), declined -10.45% to $146.76, during its last trading session.

Valeant Pharmaceuticals International, declared third quarter financial results for 2015.

Today, we stated yet another successive quarter of strong financial results that exceeded expectations, stated J. Michael Pearson, chairman and chief executive officer. I am incredibly proud of the hard work and effort put forth by Valeants employees around the world. I would also like to thank all the doctors who prescribe our products and the patients who use them. We will be discussing our outperformance on our conference call later recently, in addition to addressing the most frequently asked questions we have been hearing from our shareholders. With our strong product portfolio and growth prospects, we feel very confident in our future outlook and we are reaffirming our $7.5 billion EBITDA floor for 2016.

2015 Third Quarter Results

  • Total Revenues of $2.8 billion; an improvement of 36% over the prior year despite negative foreign exchange impact of $172 million
  • Same store sales organic growth of 13%; 5th successive quarter of > 10% organic growth, driven by:
  • Continued outperformance of U.S. businesses, particularly dermatology and contact lens
  • Strong results in China (23%), South Korea (15%) and Mexico (10%)
  • Total company growth was 8.2% volume and 4.4% price
  • S. branded pharmaceuticals growth was 18.8% volume and 15.2% price
  • Not Taking Into Account the impact from genericization of Targretin Capsules during the quarter, same store sales organic growth would have been 14%
  • Impact from generic Xenazine predictable fully in fourth quarter
  • Salix revenue was $461 million

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.

Finally, Shares of Procter & Gamble Co (NYSE:PG), ended its last trade with -0.93% loss, and closed at $74.46.

Procter & Gamble, is down -8.81% over 12 months and trades at 17.29 times forward earnings. The consensus price target is $81.29. The Company recently closed at $74.43, down -0.97%. The company has a market cap of $201.94B. The P/E ratio is 24.32.

The Procter & Gamble Company, together with its auxiliaries, manufactures and sells branded consumer packaged products worldwide. It operates through five segments: Beauty, Hair and Personal Care; Grooming; Health Care; Fabric Care and Home Care; and Baby, Feminine and Family Care.


This article is published by The content included in this article is just for informational purposes only. takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.

Neither nor any of partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.

Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by

Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.

About Travis Garlick 1803 Articles
Been writing about and trading stocks since 2013. Manage a group of micro-cap investors on Facebook with over 15,000 members. Turned $8,500 into 185k the first year I started trading stocks and haven't looked back.